SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-138316
Filing Date
2024-05-14
Accepted
2024-05-14 16:40:57
Documents
17
Period of Report
2024-05-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d846176d8k.htm   iXBRL 8-K 29781
2 EX-1.1 d846176dex11.htm EX-1.1 122775
3 EX-5.1 d846176dex51.htm EX-5.1 7885
4 EX-10.1 d846176dex101.htm EX-10.1 43392
8 GRAPHIC g846176g0514115250292.jpg GRAPHIC 2534
  Complete submission text file 0001193125-24-138316.txt   379999

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA allo-20240513.xsd EX-101.SCH 2842
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE allo-20240513_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE allo-20240513_pre.xml EX-101.PRE 10807
20 EXTRACTED XBRL INSTANCE DOCUMENT d846176d8k_htm.xml XML 3518
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 24945171
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)